Day case discharge of patients treated with drug coated balloon only angioplasty for de novo coronary artery disease: A single center experience.
Aged
Angioplasty, Balloon, Coronary
/ adverse effects
Cardiac Catheters
Clinical Protocols
Coated Materials, Biocompatible
Coronary Artery Disease
/ diagnostic imaging
England
Equipment Design
Female
Hospitals, High-Volume
Humans
Length of Stay
Male
Middle Aged
Patient Discharge
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
DCB-only angioplasty
day case
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
10
12
2018
accepted:
23
03
2019
pubmed:
9
4
2019
medline:
15
9
2020
entrez:
9
4
2019
Statut:
ppublish
Résumé
To report our initial experience with drug coated balloon (DCB) only angioplasty and propose a protocol to achieve this safely. There are no articles published in the literature currently regarding the safety of same day discharge in patients treated with DCB-only angioplasty. Retrospective review of all our patients treated with DCB-only angioplasty from September 2017 to April 2018 with identification of potential complications relating to same day discharge. A total of 100 consecutive patients who underwent elective DCB-only angioplasty for de novo coronary artery disease and were discharged on the same day as the procedure were included. In 99% no cardiac symptoms relating to the procedure requiring urgent hospitalization or urgent investigations were identified. One patient was readmitted the next day requiring stenting of the previously treated lesion. Our 30-day mortality was zero. Some 97 hospital bed days were saved with 100 patients treated. Elective day-case DCB-only angioplasty according to our local protocol is safe and cost-effective and should be considered for the majority of the patients.
Sections du résumé
OBJECTIVE
To report our initial experience with drug coated balloon (DCB) only angioplasty and propose a protocol to achieve this safely.
BACKGROUND
There are no articles published in the literature currently regarding the safety of same day discharge in patients treated with DCB-only angioplasty.
METHODS
Retrospective review of all our patients treated with DCB-only angioplasty from September 2017 to April 2018 with identification of potential complications relating to same day discharge.
RESULTS
A total of 100 consecutive patients who underwent elective DCB-only angioplasty for de novo coronary artery disease and were discharged on the same day as the procedure were included. In 99% no cardiac symptoms relating to the procedure requiring urgent hospitalization or urgent investigations were identified. One patient was readmitted the next day requiring stenting of the previously treated lesion. Our 30-day mortality was zero. Some 97 hospital bed days were saved with 100 patients treated.
CONCLUSION
Elective day-case DCB-only angioplasty according to our local protocol is safe and cost-effective and should be considered for the majority of the patients.
Substances chimiques
Coated Materials, Biocompatible
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-108Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2019 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-65.
Jeger RV, Farah A, Ohlow M, et al. Drug-coated balloons for small coronary artery disease non-inferiority. Trial. 2018;6736(18):1-8.
Wickramarachchi U, Eccleshall S. Drug-coated balloon-only angioplasty for native coronary disease instead of stents. Interv Cardiol Rev. 2016;11(2):110-115.
Kumar S, Anantharaman R, Das P, et al. Radial approach to day case intervention in coronary artery lesions (RADICAL): a single Centre safety and feasibility study. Heart. 2004;90(11):1340-1341.
Kiemeneij F, Laarman GJ, Slagboom T, Van Der Wieken R. Outpatient coronary stent implantation. J Am Coll Cardiol. 1997;29(2):323-327.
Cortese B, Silva Orrego P, Agostoni P, et al. Effect of drug-coated balloons in native coronary artery disease left with a dissection. JACC Cardiovasc Interv. 2015;8(15):2003-2009.
Black AJ, Namay DL, Niederman AL, et al. Tear or dissection after coronary angioplasty. Morphologic correlates of an ischemic complication. Circulation. 1989;79(5):1035-1042.
Rahman Z, Ullah M, Choudhury AK. coronary artery dissection and perforation complicating percutaneous coronary intervention - A review. Cardiovascular Journal. 2011;12(2):239-247.
Ludman PF, Gavalova L. National audit of percutaneous coronary interventions annual report. 2015.
Theuerle J, Yudi M, Farouque O, et al. Utility of the ACC/AHA lesion classification as a predictor of procedural, 30-day and 12-month outcomes in the contemporary percutaneous coronary intervention era. Catheter Cardiovasc Interv. 2018;92(3):227-234.
Albertal M, Van LG, Regar E, et al. Uncomplicated moderate coronary artery dissections after balloon angioplasty: good outcome without stenting. Heart. 2001;86:193-198.
Merinopoulos I, Gunawardena T, Wickramarachchi U, Ryding A, Eccleshall S, Vassiliou V. Percutaneous coronary intervention in the elderly: are drug-coated balloons the future? Curr Cardiol Rev. 2018;14(1):45-52.
Reference costs 2015-16. Department of Health. 2016.
Amin AP, Pinto D, House JA, et al. Association of same-day discharge after elective percutaneous coronary intervention in the United States with costs and outcomes. JAMA Cardiol. 2018;63110:1-9.
Rinfret S, Kennedy WA, Lachaine J, et al. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. JACC Cardiovasc Interv. 2010;3(10):1011-1019.